These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 33934114)
1. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. van Son MJ; Peters M; Reddy D; Shah TT; Hosking-Jervis F; Robinson S; Lagendijk JJW; Mangar S; Dudderidge T; McCracken S; Hindley RG; Emara A; Nigam R; Persad R; Virdi J; Lewi H; Moore C; Orczyk C; Emberton M; Arya M; Ahmed HU; van der Voort van Zyp JRN; Winkler M; Falconer A Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1120-1128. PubMed ID: 33934114 [TBL] [Abstract][Full Text] [Related]
2. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865 [TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951 [TBL] [Abstract][Full Text] [Related]
5. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677 [TBL] [Abstract][Full Text] [Related]
6. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis. Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223 [TBL] [Abstract][Full Text] [Related]
7. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455 [TBL] [Abstract][Full Text] [Related]
8. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Shah TT; Reddy D; Peters M; Ball D; Kim NH; Gomez EG; Miah S; Evans DE; Guillaumier S; van Rossum PSN; Van Son MJ; Hosking-Jervis F; Dudderidge T; Hindley R; Emara A; McCracken S; Greene D; Nigam R; McCartan N; Valerio M; Minhas S; Afzal N; Lewi H; Ogden C; Persad R; Virdi J; Moore CM; Arya M; Emberton M; Ahmed HU; Winkler M Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):567-574. PubMed ID: 33504940 [TBL] [Abstract][Full Text] [Related]
9. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843 [TBL] [Abstract][Full Text] [Related]
10. Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Emam A; Hermann G; Attwood K; Ji W; James G; Kuettel M; Mohler JL Prostate; 2021 Mar; 81(4):223-230. PubMed ID: 33471385 [TBL] [Abstract][Full Text] [Related]
11. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475 [TBL] [Abstract][Full Text] [Related]
12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995 [TBL] [Abstract][Full Text] [Related]
13. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656 [TBL] [Abstract][Full Text] [Related]
14. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807 [TBL] [Abstract][Full Text] [Related]
15. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience. Habashy D; Reddy D; Peters M; Shah TT; van Son M; van Rossum PSN; Tanaka MB; Cullen E; Engle R; McCracken S; Greene D; Hindley RG; Emara A; Nigam R; Orczyk C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU; Dudderidge T J Urol; 2023 Jul; 210(1):108-116. PubMed ID: 37014172 [TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
18. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750 [TBL] [Abstract][Full Text] [Related]
19. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027 [TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]